Literature DB >> 18636313

Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.

Rena Morita1, Satoshi Hashino2, Shinichi Shirai2, Noriaki Fujita2, Masahiro Onozawa2, Kaoru Kahata2, Takeshi Kondo2, Masahiro Imamura3, Masahiro Asaka2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18636313     DOI： 10.1007/s12185-008-0140-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

Review 1.  Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?

Authors:  E D Batts; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2007-07-02       Impact factor: 5.483

Review 2.  Thrombotic microangiopathy during pregnancy.

Authors:  K R McCrae; D B Cines
Journal:  Semin Hematol       Date:  1997-04       Impact factor: 3.851

Review 3.  Human immunodeficiency virus infection and thrombotic microangiopathy.

Authors:  K B Hymes; S Karpatkin
Journal:  Semin Hematol       Date:  1997-04       Impact factor: 3.851

4.  Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Authors:  P Iacopino; G Pucci; W Arcese; A Bosi; M Falda; F Locatelli; P Marenco; R Miniero; F Morabito; F Rossetti; S Sica; C Uderzo; A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  1999-07       Impact factor: 5.483

5.  Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.

Authors:  J C Moore; C P Hayward; T E Warkentin; J G Kelton
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

Authors:  P M Mannucci; M T Canciani; I Forza; F Lussana; A Lattuada; E Rossi
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

Review 7.  Drug-induced thrombotic microangiopathy.

Authors:  Anaadriana Zakarija; Charles Bennett
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

8.  Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation.

Authors:  Amy Belford; Otha Myles; Alan Magill; James Wang; Rick C Myhand; Jamie K Waselenko
Journal:  Am J Hematol       Date:  2004-06       Impact factor: 10.047
  8 in total
  9 in total

Review 1.  Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Authors:  Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G Glezerman; Divya Monga; Mitchell Rosner; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

2.  Bortezomib-induced thrombotic thrombocytopaenic purpura.

Authors:  Neha Mehta; Ashish Saxena; Ruben Niesvizky
Journal:  BMJ Case Rep       Date:  2012-08-01

3.  Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma.

Authors:  Urpu Salmenniemi; Kari Remes
Journal:  Hematol Rep       Date:  2012-06-29

4.  Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.

Authors:  Liliane Hobeika; Sally E Self; Juan Carlos Q Velez
Journal:  BMC Nephrol       Date:  2014-09-30       Impact factor: 2.388

5.  Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.

Authors:  Clarissa A Cassol; Michael P A Williams; Tiffany N Caza; Sophia Rodriguez
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

6.  Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy.

Authors:  Robert C Sterner; William Nicholas Rose
Journal:  Hematol Rep       Date:  2022-04-05

Review 7.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

Review 8.  Thrombotic microangiopathy associated with proteasome inhibitors.

Authors:  Ahad Lodhi; Abhishek Kumar; Muhammad U Saqlain; Manish Suneja
Journal:  Clin Kidney J       Date:  2015-07-16

9.  Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.

Authors:  Jan Van Keer; Michel Delforge; Daan Dierickx; Kathelijne Peerlinck; Evelyne Lerut; Ben Sprangers
Journal:  Case Rep Hematol       Date:  2016-05-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.